Not yet, Veli is working on this. We shall discuss this next week in
Brussels at the STEP conference.

Marco


>Dear All,
>some of us will be in Brussels for the conference/ "concertation"
>meeting (in my case, because
>of the @neurIST project), so participation in a workshop on the preceeding day
>would be possible, if it were open to new participants. Is there
>more info available ?
>Cheers,
>Guy
>------------------------------------------------------------------------
>Dr. Guy Lonsdale
>General Manager
>C&C Research Laboratories, NEC Europe Ltd.
>Rathausallee 10
>D-53757 St. Augustin, Germany
>Tel. +49-2241-92520; Fax. +49-2241-925299
>----- Original Message -----
>From: Marco Viceconti
>To: The STEP Action public forum
>Sent: Sunday, May 07, 2006 9:35 AM
>Subject:Impact of VPH on patient safetyand risk management
>
>
>Dear Colleagues:
>I have been contacted by Veli N. Stroetmann, of Empirica (DE), and
>expert of ICT impact analysis who is coordinating an ERA-NET action
>on E-Health. Veli is organising a small workshop on June 28 in
>conjuction with the conference on "ICT for BIO-Medical Sciences" -
>29-30 June 2006 in Brussels, to brainstorm, among the other arguments
>on the opportunities and benefits from modelling and simulation
>of human physiology and disease related processes in this context.
>
>From a preliminary survey she did, also on the basis of a visit to
>Peter Hunter lab, she foresee concrete examples from
>the Physiome: e.g. less CTs for follow up after hip replacement
>(reduced radiation), early diagnosis of heart diseases, planning of
>surgery (cerebroplasia), but also future work on"understanding how
>model parameters are affected by individual variation, by
>embryological growth, by ageing and by disease, that will
>bring additional enormous benefits to the design of medical devices,
>the diagnosis and treatment of disease and the development of new
>drugs" etc.
>
>I guess we, as STEP experts, should try to give a broader definition
>of the potential impact of the VPH on safety and risk management.
>Thus, I invited Vesi to join this forum, and I would ask all of you
>to reply to this message with any idea you might have on this
>particular aspect.
>
>My two cents:
>
>VPH is an integrative multiscale model. From this we can derive some
>general features associated to safety:
>
>- VPH is predictive: this means that we can predict a number of
>problems before we actually observe them in our patients. The
>potential impact is strong in reducing the risk in clinical trials of
>drugs and devices; in a longer time it may become significant also
>the risk reduction for the single patient.
>
>- VPH is integrative: this means that VPH can help to discover
>interdependencies between physiological subsystems that are a major
>source of unexpected complications. This is particularly true in
>rare diseases where the knowledge accumulation process of VPH may be
>highlight conditions hardly observable otherwise, and in diseases
>with a strong systemic component such as osteoporosis, cancer and
>cardiovascular pathologies.
>
>- VPH is multiscale: by elucidating the interaction between gene,
>cells, tissues and organs VPH can provide a much broader perspective
>in risk management associated to new drugs.
>
>28-6-2006 we already have planned a STEP consortium meeting, so
>nobody of us can participate to Veli workshop. However, if any of
>you is available on that date and has in interest in this matter,
>please let me know, we might ask you to represent the VPH concept in
>that workshop.
>
>Regards
>
>
>--
>--------------------------------------------------
>MARCO VICECONTI, PhD (viceconti@tecno.ior.it)
>Laboratorio di Tecnologia Medica tel. 39-051-6366865
>Istituti Ortopedici Rizzoli fax. 39-051-6366863
>via di barbiano 1/10, 40136 - Bologna, Italy
>
>Tiger! Tiger! Burning bright in the forest of the night,
>what immortal hand or eye could frame thy fearful symmetry?
>--------------------------------------------------
>Opinions expressed here do not necessarily reflect those of my employer
>
>
>original:
><http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public/745500783243>http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public/745500783243
>_____________________________
>"The STEP Action public forum"
><http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public>http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public
>"Biomed Town" <http://www.biomedtown.org>http://www.biomedtown.org
>
>
><http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public/253022108514>original
>_____________________________
><http://www.biomedtown.org/biomed_town/VPH/StepPublic/step-public>The
>STEP Action public forum
><http://www.biomedtown.org>Biomed Town


--
--------------------------------------------------
MARCO VICECONTI, PhD (viceconti@tecno.ior.it)
Laboratorio di Tecnologia Medica tel. 39-051-6366865
Istituti Ortopedici Rizzoli fax. 39-051-6366863
via di barbiano 1/10, 40136 - Bologna, Italy

Tiger! Tiger! Burning bright in the forest of the night,
what immortal hand or eye could frame thy fearful symmetry?
--------------------------------------------------
Opinions expressed here do not necessarily reflect those of my employer